IGC (IGC Pharma Inc) Utang jangka cendhak marang modal

The IGC Pharma, Inc. (IGC) price chart demonstrates the 0.17 metric. Initial drug trials serve as a promising factor, although the probability of development failure is already priced in. The business faces a funding shortage and legal uncertainty regarding the creation of CNS drugs. IGC Pharma, Inc. (IGC) is seeking unconventional dementia therapies by targeting brain cells using cannabis derivatives.

Investors expect high financial stability from biotech startups, particularly when dealing with risky cannabinoid drugs and volatile clinical trials. By analyzing the current debt-to-equity ratio, we assess the proportion of short-term liabilities within the financing structure, which determines the ability of IGC Pharma, Inc. (IGC) to service its debts without compromising operational activities amid regulatory uncertainty.